معرفی
Dr. Dag Aarsland is a prominent neurodegenerative disease researcher at Newcastle University, specializing in dementia with Lewy bodies (DLB), Alzheimer's disease, and Parkinson's-related cognitive impairment. As a key contributor to the DLB Consortium, he has shaped international diagnostic criteria through multiple consensus reports. His work bridges molecular mechanisms, clinical diagnostics, and therapeutic development.
His research focuses on:
- Diagnostic criteria development for prodromal and mild cognitive impairment stages
- Sex-specific neurodegeneration patterns and biomarker validation
- Multimodal neuroimaging (EEG, MRI) and molecular pathway analysis
- Therapeutic target identification for amyloid-β and tau pathologies
Analysis of his 2017-2025 publications reveals consistent leadership in DLB research, with increasing emphasis on multicenter validation studies (2025 EEG work), AI-driven diagnostics (2020 deep learning MRI), and sex-differentiated analysis (2024 brain atrophy study). His work demonstrates strong translational impact through DLB Consortium guidelines while maintaining rigorous basic science investigation.
Dr. Aarsland maintains extensive national and international collaborations, particularly through the DLB Consortium, working with leading researchers including Professor Ian McKeith, Professor John-Paul Taylor, and Dr. Clive Ballard. His continuous publication record indicates active grant funding supporting multicenter clinical studies and translational research programs.
